Skip to main content
Erschienen in: Annals of Hematology 11/2018

27.06.2018 | Original Article

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms

verfasst von: Prajwal Boddu, Dai Chihara, Lucia Masarova, Naveen Pemmaraju, Keyur P. Patel, Srdan Verstovsek

Erschienen in: Annals of Hematology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by proliferation of one or more elements of the myeloid lineage. Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs. While thought to be mutually exclusive, occasional isolated reports of coexistence of BCR-ABL1 and JAK2, and JAK2 with MPL or CALR aberrations have been described. Given the paucity of data, clinical characteristics and outcome of patients harboring concurrent Philadelphia-positive and Philadelphia-negative mutations or dual Philadelphia-negative driver mutations have not been systematically evaluated, and their clinical relevance is largely unknown. It is difficult to determine the true relevance of co-existing driver mutations on outcomes given the rarity of its occurrence. In this case series, we describe those patients who had dual driver mutations detected at any point during the course of their disease and characterized their clinical and laboratory features, bone marrow pathology, and overall disease course.
Literatur
1.
Zurück zum Zitat Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370–3373CrossRef Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370–3373CrossRef
2.
Zurück zum Zitat Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Büsche G, Kreipe H (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22(5):1059–1062CrossRef Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, Büsche G, Kreipe H (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22(5):1059–1062CrossRef
3.
Zurück zum Zitat Pingali SR et al (2009) Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 9(5):E25–E29CrossRef Pingali SR et al (2009) Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 9(5):E25–E29CrossRef
4.
Zurück zum Zitat Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, Najfeld V (2013) BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood 121(7):1238–1239CrossRef Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, Najfeld V (2013) BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood 121(7):1238–1239CrossRef
5.
Zurück zum Zitat Zhou A, Knoche EM, Engle EK, Fisher DAC, Oh ST (2015) Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5:e351CrossRef Zhou A, Knoche EM, Engle EK, Fisher DAC, Oh ST (2015) Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5:e351CrossRef
6.
Zurück zum Zitat Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C (2008) JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22(7):1454–1455CrossRef Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, Laï JL, Rose C, Preudhomme C (2008) JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22(7):1454–1455CrossRef
7.
Zurück zum Zitat Iurlo A, Gianelli U, Rapezzi D, Cattaneo D, Fermo E, Binda F, Santambrogio E, Bucelli C, Cortelezzi A (2014) Imatinib and ruxolitinib association: first experience in two patients. Haematologica 99(6):e76–e77CrossRef Iurlo A, Gianelli U, Rapezzi D, Cattaneo D, Fermo E, Binda F, Santambrogio E, Bucelli C, Cortelezzi A (2014) Imatinib and ruxolitinib association: first experience in two patients. Haematologica 99(6):e76–e77CrossRef
8.
Zurück zum Zitat Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N (2010) A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 91(1):136–139CrossRef Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N (2010) A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 91(1):136–139CrossRef
9.
Zurück zum Zitat Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI (2015) Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J 56(1):74–76CrossRef Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI (2015) Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J 56(1):74–76CrossRef
10.
Zurück zum Zitat Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP (2015) Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360–3363CrossRef Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP (2015) Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360–3363CrossRef
11.
Zurück zum Zitat Bocchia, M., Vannucchi A.M., Gozzetti A., Guglielmelli P., Poli G., Crupi R., Defina M., Bosi A., Francesco L., Insights into JAK2-V617F mutation in CML. Lancet Oncol, 2007. 8(10): p. 864–6, 866CrossRef Bocchia, M., Vannucchi A.M., Gozzetti A., Guglielmelli P., Poli G., Crupi R., Defina M., Bosi A., Francesco L., Insights into JAK2-V617F mutation in CML. Lancet Oncol, 2007. 8(10): p. 864–6, 866CrossRef
12.
Zurück zum Zitat Campiotti L, Appio L, Solbiati F, Ageno W, Venco A (2009) JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 33(11):e212–e213CrossRef Campiotti L, Appio L, Solbiati F, Ageno W, Venco A (2009) JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 33(11):e212–e213CrossRef
13.
Zurück zum Zitat Kramer A et al (2007) JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8(7):658–660CrossRef Kramer A et al (2007) JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8(7):658–660CrossRef
14.
Zurück zum Zitat Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K (2013) Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol 2(1):24CrossRef Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K (2013) Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol 2(1):24CrossRef
15.
Zurück zum Zitat Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K (2007) Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21(5):1103–1104CrossRef Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K (2007) Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21(5):1103–1104CrossRef
16.
Zurück zum Zitat McGaffin G, Harper K, Stirling D, McLintock L (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol 167(2):276–278CrossRef McGaffin G, Harper K, Stirling D, McLintock L (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol 167(2):276–278CrossRef
17.
Zurück zum Zitat Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477CrossRef Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472–1477CrossRef
18.
Zurück zum Zitat Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220–2228CrossRef Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220–2228CrossRef
19.
Zurück zum Zitat Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112(1):141–149CrossRef Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112(1):141–149CrossRef
20.
Zurück zum Zitat Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM, GIMEMA--Italian Registry of Myelofibrosis, MPD Research Consortium (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137(3):244–247CrossRef Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM, GIMEMA--Italian Registry of Myelofibrosis, MPD Research Consortium (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137(3):244–247CrossRef
21.
Zurück zum Zitat Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS (2002) Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol 13(5):781–788CrossRef Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS (2002) Quantitative measurement of BCR/abl transcripts using real-time polymerase chain reaction. Ann Oncol 13(5):781–788CrossRef
22.
Zurück zum Zitat Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35–45CrossRef Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35–45CrossRef
23.
Zurück zum Zitat DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732–736CrossRef DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732–736CrossRef
24.
Zurück zum Zitat McGowan-Jordan A,S.M., Schmid M. An international system for human cytogenetic normenclature (ISCN 2016), recommendations of the international standing committee on human cytogenetic normenclature, Karger, Base, Switzerland (2016 ) McGowan-Jordan A,S.M., Schmid M. An international system for human cytogenetic normenclature (ISCN 2016), recommendations of the international standing committee on human cytogenetic normenclature, Karger, Base, Switzerland (2016 )
25.
Zurück zum Zitat Biernaux C et al (1996) Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant 17(Suppl 3):S45–S47PubMed Biernaux C et al (1996) Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant 17(Suppl 3):S45–S47PubMed
26.
Zurück zum Zitat Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92(9):3362–3367PubMed Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92(9):3362–3367PubMed
27.
Zurück zum Zitat Aviram A, Blickstein D, Stark P, Luboshitz J, Bairey O, Prokocimer M, Shaklai M (1999) Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 33(1–2):77–82CrossRef Aviram A, Blickstein D, Stark P, Luboshitz J, Bairey O, Prokocimer M, Shaklai M (1999) Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 33(1–2):77–82CrossRef
28.
Zurück zum Zitat Hsu HC, Tan LY, Au LC, Lee YM, Lieu CH, Tsai WH, You JY, Liu MD, Ho CK (2004) Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia. J Lab Clin Med 143(2):125–129CrossRef Hsu HC, Tan LY, Au LC, Lee YM, Lieu CH, Tsai WH, You JY, Liu MD, Ho CK (2004) Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia. J Lab Clin Med 143(2):125–129CrossRef
29.
Zurück zum Zitat Hackwell S, Ross F, Cullis JO (1999) Patients with essential thrombocythemia do not express BCR-ABL transcripts. Blood 93(7):2420–2421PubMed Hackwell S, Ross F, Cullis JO (1999) Patients with essential thrombocythemia do not express BCR-ABL transcripts. Blood 93(7):2420–2421PubMed
30.
Zurück zum Zitat Damaj G, Delabesse E, le Bihan C, Asnafi V, Rachid M, Lefrere F, Radford-Weiss I, Macintyre E, Hermine O, Varet B (2002) Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 116(4):812–816CrossRef Damaj G, Delabesse E, le Bihan C, Asnafi V, Rachid M, Lefrere F, Radford-Weiss I, Macintyre E, Hermine O, Varet B (2002) Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 116(4):812–816CrossRef
31.
Zurück zum Zitat Yamada H, Murakami T, Kaneda T, Tadachi M, Utsumi M, Minami S, Hamaguchi M, Kasai M, Kodera Y, Ohashi H, Morishita Y, Terasawa T, Yamasaki Y, Kamiya Y, Hattori M, Yamanaka K, Tsushita K, Shimoyama M (2000) Clinical significance of major and minor bcr/abl chimeric transcripts in essential thrombocythemia. Jpn J Clin Oncol 30(11):472–477CrossRef Yamada H, Murakami T, Kaneda T, Tadachi M, Utsumi M, Minami S, Hamaguchi M, Kasai M, Kodera Y, Ohashi H, Morishita Y, Terasawa T, Yamasaki Y, Kamiya Y, Hattori M, Yamanaka K, Tsushita K, Shimoyama M (2000) Clinical significance of major and minor bcr/abl chimeric transcripts in essential thrombocythemia. Jpn J Clin Oncol 30(11):472–477CrossRef
32.
Zurück zum Zitat Kwong YL, Chiu EKW, Liang RHS, Chan V, Chan TK (1996) Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet 89(1):74–76CrossRef Kwong YL, Chiu EKW, Liang RHS, Chan V, Chan TK (1996) Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet 89(1):74–76CrossRef
33.
Zurück zum Zitat Heller P, Kornblihtt LI, Cuello MT, Larripa I, Najfeld V, Molinas FC (2001) BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood 98(6):1990–1991CrossRef Heller P, Kornblihtt LI, Cuello MT, Larripa I, Najfeld V, Molinas FC (2001) BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood 98(6):1990–1991CrossRef
34.
Zurück zum Zitat Pajor L, Kereskai L, Zsdral K, Nagy Z, Vass JA, Jakso P, Radvanyi G (2003) Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation. Histopathology 42(1):53–60CrossRef Pajor L, Kereskai L, Zsdral K, Nagy Z, Vass JA, Jakso P, Radvanyi G (2003) Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation. Histopathology 42(1):53–60CrossRef
35.
Zurück zum Zitat Nafe R et al (1995) Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases. Pathologe 16(1):34–40CrossRef Nafe R et al (1995) Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases. Pathologe 16(1):34–40CrossRef
36.
Zurück zum Zitat Vardiman JW (2009) Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 132(2):250–260CrossRef Vardiman JW (2009) Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 132(2):250–260CrossRef
37.
Zurück zum Zitat Bornhauser M et al (2007) Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21(8):1824–1826CrossRef Bornhauser M et al (2007) Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21(8):1824–1826CrossRef
38.
Zurück zum Zitat Strom SP (2016) Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med 13(1):3–11CrossRef Strom SP (2016) Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med 13(1):3–11CrossRef
39.
Zurück zum Zitat Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gary Gilliland D, Tefferi A (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135(5):683–687CrossRef Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gary Gilliland D, Tefferi A (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135(5):683–687CrossRef
40.
Zurück zum Zitat Gundabolu K et al (2015) Concurrent somatic mutations in exon 14 of Janus KINASE2 (JAK2) and exon 10 of myeloprolifeative leukemia virus oncogene (MPL) in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)/MPN. Blood 126(23):5211–5211 Gundabolu K et al (2015) Concurrent somatic mutations in exon 14 of Janus KINASE2 (JAK2) and exon 10 of myeloprolifeative leukemia virus oncogene (MPL) in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)/MPN. Blood 126(23):5211–5211
41.
Zurück zum Zitat Martinaud C, Brisou P, Mozziconacci MJ (2010) Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 85(4):287–288CrossRef Martinaud C, Brisou P, Mozziconacci MJ (2010) Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 85(4):287–288CrossRef
42.
Zurück zum Zitat Sidon P, el Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9):1622CrossRef Sidon P, el Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9):1622CrossRef
43.
Zurück zum Zitat Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70–79CrossRef Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70–79CrossRef
44.
Zurück zum Zitat Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jager R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R (2016) Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 127(3):325–332CrossRef Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jager R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R (2016) Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 127(3):325–332CrossRef
45.
Zurück zum Zitat Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME (2016) Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk Lymphoma 57(6):1429–1435CrossRef Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME (2016) Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk Lymphoma 57(6):1429–1435CrossRef
46.
Zurück zum Zitat Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092–1097CrossRef Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092–1097CrossRef
47.
Zurück zum Zitat Favaa C, C.G., Ferrero D, Ulisciania S, Serraa A, Coexistence of a JAK2 mutated clone may cause hematologic resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma, 2009. 9 (6): p. E41CrossRef Favaa C, C.G., Ferrero D, Ulisciania S, Serraa A, Coexistence of a JAK2 mutated clone may cause hematologic resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma, 2009. 9 (6): p. E41CrossRef
48.
Zurück zum Zitat Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109–121CrossRef Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109–121CrossRef
Metadaten
Titel
The co-occurrence of driver mutations in chronic myeloproliferative neoplasms
verfasst von
Prajwal Boddu
Dai Chihara
Lucia Masarova
Naveen Pemmaraju
Keyur P. Patel
Srdan Verstovsek
Publikationsdatum
27.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3402-x

Weitere Artikel der Ausgabe 11/2018

Annals of Hematology 11/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.